According to a new PALLAS research, palbociclib did not increase metastatic disease-free survival when added to adjuvant endocrine therapy for individuals with early-stage HR+/HER2-breast cancer as compared with adjuvant endocrine therapy alone. The gene discussed is ERBB2; the disease is breast carcinoma.